Evidence map›Paper›PMID 36520863›Full record

ArticlePloS one2022

Prevention of 90-day inpatient detoxification readmission for opioid use disorder by a community-based life-changing individualized medically assisted evidence-based treatment (C.L.I.M.B.) program: A quasi-experimental study.

Zhehui Luo, Canopy Roychoudhury, William S Pompos, James DiMaria, Cynthia M Robinette, Purva H Gore, Rohon Roychoudhury, William Beecroft

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zhehui LuoDepartment of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan, United States of America.ORCID 0000-0001-9193-3380
Canopy RoychoudhuryHealth Care Value Business Analytics Services, Blue Cross Blue Shield of Michigan, Detroit, Michigan, United States of America.
William S PomposBehavioral Health Strategy & Planning, Blue Cross Blue Shield of Michigan, Detroit, Michigan, United States of America.
James DiMariaHealth Care Value Business Analytics Services, Blue Cross Blue Shield of Michigan, Detroit, Michigan, United States of America.
Cynthia M RobinetteHealth Care Value Business Analytics Services, Blue Cross Blue Shield of Michigan, Detroit, Michigan, United States of America.
Purva H GoreHealth Care Value Business Analytics Services, Blue Cross Blue Shield of Michigan, Detroit, Michigan, United States of America.
Rohon RoychoudhuryCollege of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, United States of America.ORCID 0000-0003-0437-9276
William BeecroftBehavioral Health Strategy & Planning, Blue Cross Blue Shield of Michigan, Detroit, Michigan, United States of America.
Blue Cross Blue Shield of Michigan Foundation · USMichigan United · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvidence for community-based strategies to reduce inpatient detoxification readmission for opioid use disorder (OUD) is scant. A pilot program was designed to provide individualized structured treatment plans, including addressing prolonged withdrawal symptoms, family/systems assessment, and contingency management, to reduce readmission after the index inpatient detoxification.

methodsA non-randomized quasi-experimental design was used to compare the pilot facilities (treatment) and comparison facilities before and after the program started, i.e., a simple difference-in-differences (DID) strategy. Adults 18 years and older who met the Diagnostic and Statistical Manual of Mental Disorders version 5 criteria for OUD and had an inpatient detoxification admission at any OUD treatment facility in two study periods between 7/2016 and 3/2020 were included. Readmission for inpatient detoxification in 90-days after the index stay was the primary outcome, and partial hospitalization, intensive outpatient care, outpatient services, and medications for OUD were the secondary outcomes. Six statistical estimation methods were used to triangulate evidence and adjust for potential confounding factors between treatment and comparison groups.

resultsA total of 2,320 unique patients in the pilot and comparison facilities with 2,443 index inpatient detoxification admissions in the pre- and post-periods were included. Compared with patients in comparison facilities, patients in the C.L.I.M.B. facilities had higher readmission in the pre-period (unadjusted readmission 17.0% vs. 10.6%), but similar rates in the post-period (12.3% vs. 10.6%) after the implementation of the pilot program. For 90-day readmission, all DID estimates were not statistically significant (adjusted estimates ranged from 6 to 9 percentage points difference favoring the C.L.I.M.B. program). There was no significant improvement in the secondary outcomes of utilizations in lower level of care and medications for OUD in C.L.I.M.B. facilities.

conclusionsWe found a reduction in readmission in the pilot facilities between the two periods, but the results were not statistically significant compared with the comparison facilities and the utilization of lower level of care services remained low. Even though providers in the pilot OUD treatment facilities actively worked with health plans to standardize care for patients with OUD, more strategies are needed to improve treatment engagement and retention after an inpatient detoxification.

Indexed as

InpatientsOpioid-Related DisordersAdultDay Care, MedicalHospitalizationHumansPatient Readmission

Identifiers

PMID36520863
PMCPMC9754176
OpenAlexW4311602064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.